Provided by Tiger Trade Technology Pte. Ltd.

AngioDynamics

16.13
+0.28001.77%
Post-market: 16.130.00000.00%19:30 EDT
Volume:358.53K
Turnover:5.75M
Market Cap:664.55M
PE:-18.23
High:16.22
Open:15.80
Low:15.63
Close:15.85
52wk High:16.29
52wk Low:9.39
Shares:41.20M
Float Shares:36.08M
Volume Ratio:1.50
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8848
EPS(LYR):-0.8848
ROE:-20.77%
ROA:-5.13%
PB:3.89
PE(LYR):-18.23

Loading ...

Angiodynamics Outlook FY Adjusted EPS USD -0.29 to -0.24

THOMSON REUTERS
·
Jul 14

Angiodynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-year Profitability

THOMSON REUTERS
·
Jul 14

U.S. Earnings Preview: Before Market Open July 14

Dow Jones
·
Jul 14

Top News Today: Stocks Fall as Chip Makers Slide, Oil Spikes

Dow Jones
·
Jul 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 13

Angiodynamics Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview

Reuters
·
Jul 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 08

Press Release: Angiodynamics to Report Fiscal 2026 Fourth Quarter and Full-year Financial Results on July 14, 2026

Dow Jones
·
Jun 30

Angiodynamics to Report Fiscal 2026 Fourth-quarter and Full-year Results, Host Conference Call

Reuters
·
Jun 30

AngioDynamics Secures FDA Approval to Begin Benign Prostatic Hyperplasia Study

MT Newswires Live
·
Jun 17

AngioDynamics wins FDA IDE approval for RELIEF feasibility study of NanoKnife in BPH

Reuters
·
Jun 17

AngioDynamics Receives FDA Ide Approval for Relief Feasibility Study Evaluating Nanoknife Ire Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (Bph)

THOMSON REUTERS
·
Jun 17

AngioDynamics Targets BPH Market With New NanoKnife Trial: What Investors Should Watch

TIPRANKS
·
Jun 12

AngioDynamics lifts FY2026 net sales outlook to $313.5-$315.5 million

Reuters
·
Jun 10

BRIEF-AngioDynamics Says Palmetto GBA finalizes Medicare Nanoknife coverage from July 5, 2026

Reuters
·
May 29

AngioDynamics Medicare coverage for NanoKnife IRE in prostate, liver cancer takes effect July 2026

Reuters
·
May 29

AngioDynamics - Palmetto Gba Issues Final Lcd for Medicare Coverage of Nanoknife Ire Effective July 5, 2026

THOMSON REUTERS
·
May 29

AngioDynamics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
May 27

AngioDynamics Reports 'Durable Oncologic Control' in Study of NanoKnife for Intermediate-Risk Prostate Cancer

MT Newswires Live
·
May 13